Sign inJoin waitlistJoin the waitlist

DK

Daniel Karp

Hematology & Oncology

Credentials: · ·

History

Hematology and Medical Oncology
1976–1979
Internal Medicine
1973–1976
Duke University School of Medicine
1969–1973

Research

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
JAMA · 2009 · 1,523 citations
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
JAMA · 2011 · 1,265 citations
Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
New England Journal of Medicine · 1990 · 1,249 citations

Sarina Piha-Paul
77 papers
David Hong
76 papers
Funda Meric-Bernstam
74 papers
Siqing Fu
74 papers
Aung Naing
73 papers
Vivek Subbiah
72 papers
Apostolia Tsimberidou
63 papers
FJ
Filip Janku
58 papers
Jordi Ahnert
29 papers · 9 as a fellow
Timothy Yap
24 papers
Shubham Pant
23 papers
Ecaterina Dumbrava
21 papers

Grants

Center for Clinical and Translational Sciences (CCTS)
National Center for Advancing Translational Sciences · UL1
PI · $38M · University of Texas Hlth Sci Ctr Houston
2019–2024
The University of Texas MD Anderson Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $1.5M · University of Tx Md Anderson Can Ctr
2008–2013
Eastern Cooperative Oncology Group
National Cancer Institute · U10
Contact PI · $434.7K · Beth Israel Deaconess Medical Center
1999–2004
Eastern Cooperative Oncology Group
National Cancer Institute · U10
Contact PI · $1.9M · Tufts Medical Center
1982–1999

Clinical trials

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
Principal investigator · Completed · Phase 1, Phase 2
Promontory Therapeutics Inc.
2018–2022
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Principal investigator · Unknown · Phase 2
Promontory Therapeutics Inc.
2014–2025
Temsirolimus In Phase 0
Principal investigator · Completed · Early phase 1
M.D. Anderson Cancer Center
2010
Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients
Principal investigator · Terminated · Phase 1, Phase 2
M.D. Anderson Cancer Center
2009–2014